Recently, Legrand, the parent company of Kenall Manufacturing, and the Icahn School of Medicine at Mount Sinai in New York City, announced the publication of research showing Indigo Clean light disinfection technology effectively and safely inactivates SARS-CoV-2 and influenza A viruses in a range of real-world clinical settings. In addition, Kenall announced that the University of Tennessee (UT) Health Science Center, a BSL-3 Regional Biocontainment Laboratory, has successfully provided independent confirmation of the ground-breaking research performed by Mt. Sinai. The results validate Indigo-Clean’s value as an innovative medical technology that helps hospitals maintain patient and frontline worker safety as they deliver urgent, high-quality care.
UT performed the study using identical test equipment and procedures at a single exposure level on the same type of luminaire. The exposure level was chosen to minimize statistical variation and ensure proper comparison with the work performed at Mt. Sinai. The results, a 99.39 percent mean reduction after eight hours of irradiation, were virtually identical to those published in Nature-Scientific Reports, a Nature Publication, and confirm the Mt. Sinai findings.
Indigo-Clean has become North America’s most trusted visible light disinfection technology in hospitals, clinics, schools and public facilities, recently reaching its 500th installation. “The findings from the original research, and the validation from UT are critically important as the COVID-19 pandemic continues and flu season approaches,” says Cliff Yahnke, Ph.D., Chief Scientist and Head of Clinical Affairs at Kenall. “Indigo-Clean has already proven it kills harmful bacteria, including C. Diff and staph such as MRSA, and reduces healthcare acquired infections (HAIs). Now we can add a scientifically proven SARS-CoV-2i virucidal efficacy claim of 94 percent to our value proposition. Indigo-Clean can easily be incorporated into any healthcare system’s mitigation strategy—even as a lighting retrofit—to help prevent infections, leading to better health outcomes for patients and offering a return on investment in as little as 2.2 months.”